Reference: Anderson, S. (2020). CBER plans for monitoring COVID-19 vaccine safety and effectiveness. Vaccines and Related Biological Products Advisory Committee Meeting, FDA. Summary: The FDA’s Centre for Biologics Evaluation and Research (CBER) presented its comprehensive strategy for monitoring the safety and effectiveness of COVID-19 vaccines during the VRBPAC meeting on October 22, 2020. The approach […]
Reference: National Institutes of Health. (2020, July 27). Phase 3 clinical trial of investigational vaccine for COVID-19 begins. https://www.nih.gov/news-events/news-releases/phase-3-clinical-trial-investigational-vaccine-covid-19-begins Summary: The National Institutes of Health (NIH) has commenced a Phase 3 clinical trial to assess the efficacy of the investigational mRNA-1273 vaccine, co-developed by Moderna, Inc. and NIH’s National Institute of Allergy and Infectious Diseases
Reference: Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020). Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. The Lancet, published online May 22, https://doi.org/10.1016/S0140-6736(20)31180-6 Summary: In June 2020, The Lancet announced the retraction of a significant study assessing the effectiveness of hydroxychloroquine
Reference: U.S. Department of Health and Human Services. (2020). Contains nonbinding recommendations: Development and licensure of vaccines to prevent COVID-19 guidance for industry. Food and Drug Administration. Summary: In June 2020, the U.S. Food and Drug Administration (FDA) issued guidance to assist the development and licensure of COVID-19 vaccines amidst the public health emergency. This
Reference: Mehra, M. R., Desai, S. S., Ruschitzka, F., & Patel, A. N. (2020). Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. The Lancet, 395(10240), 1820-1830. https://doi.org/10.1016/S0140-6736(20)31180-6 Summary: The study evaluates the efficacy of hydroxychloroquine and chloroquine, either alone or in combination with macrolides, in treating COVID-19
Reference: Levy, T. E. (2020). An at-home treatment that can cure any virus, including coronavirus. Retrieved from www.PeakEnergy.com Summary: The article discusses a simple and inexpensive treatment for viral infections, including COVID-19, using 3% hydrogen peroxide. Originally conceptualised by Dr. Charles Farr, this therapy targets infected cells rather than the viruses themselves, which cannot be
Reference: Pfizer. (2020). PF-07302048 (BNT162 RNA-Based COVID-19 vaccines) protocol C4591001. Summary: The document outlines the Phase 1/2/3 clinical trial to evaluate the safety, tolerability, immunogenicity, and efficacy of BNT162 RNA-based COVID-19 vaccines, developed by Pfizer and BioNTech. The trial investigates two vaccine candidates: BNT162b1, encoding the receptor-binding domain (RBD), and BNT162b2, encoding the prefusion spike
Reference: Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261-279. https://doi.org/10.1038/nrd.2017.243 Summary: mRNA vaccines offer a potent alternative to traditional vaccine approaches due to their rapid development and cost-effective manufacturing. They have shown promise in preventing infectious diseases
Reference: Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., Ribeiro, A. (Mick), Watson, M., Zaks, T., & Ciaramella, G. (2017). Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Molecular Therapy, 25(6), 1316-1326.
Reference: Crump, A. (2017). Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations. The Journal of Antibiotics, 70(6), 495-505. https://doi.org/10.1038/ja.2017.11 Summary: Over the last decae, ivermectin has gained recognition for its significant contributions to global health. Discovered from a soil microbe in Japan, it was developed by Satoshi Ōmura and William Campbell, who